Biotech Co.* | Pharma Co. | Product | Terms/Details (Date) |
| | |||
Cobra Biomanu- facturing* (UK) | Mayne Pharma | Agreement to supply clinical trial and commercial supplies of ovine adenovirus | Mayne is combining a cell-killing technology with the ovine adenovirus technology, which is licensed from a research organization; Cobra will supply ovine adenovirus for the toxicology studies and Phase I/II trials (12/11) |
GTC | Merrimack Pharmaceuticals Inc. | ABI.001 | Agreement for GTC to begin production of Merrimack's ABI.001, a recombinant human alpha-fetoprotein to be used in clinical studies; GTC will be compensated in 2003 upon the delivery of clarified bulk product to Merrimack (10/24) |
Helix BioPharma | WellSpring Pharmaceutical Canada Corp. (Canada) | Interferon-alpha | Agreement for the manufacture of product for clinical studies planned for 2003; WellSpring will manufacture the cream for infection and disease caused by the human papillomavirus (12/17) |
Hemispherx Biopharma Inc. (AMEX:HEB) | Sigma-Aldrich Fine Chemicals (division of Sigma-Aldrich Corp.) | Ampligen | Sigma-Aldrich Fine Chemicals will manufacture the active ingredient for Hemispherx's lead RNA-based platform drug, Ampligen (11/18) |
InSite Vision Inc. | Societa Industria Farmaceutica | OcuGene genetic | Eight-year agreement in which SIFI gains rights to manufacture, distribute and promote the OcuGene genetic glaucoma test in Italy (12/17) |
KS Biomedix plc | Ranbaxy | TransMID | Marketing agreement in which Ranbaxy will have exclusive marketing rights in India in return for unspecified milestone payments; Ranbaxy also has an option to extend coverage to other Southern Asia markets (10/30**) |
Lorus Therapeutics Inc. (Canada; OTC BB:LORFF; TSE:LOR) | Mayne Pharma | Virulizin | Mayne Pharma will acquire distribution rights for Virulizin in Argentina for the treatment of malignant melanoma (11/14) |
Microbix | Merck & Co. | Helper-Dependent Adenovirus Vector technology | Agreement for Microbix to distribute the technology for Merck; financial terms were not disclosed (11/15) |
The Medicines | Oryx Pharma- | Angiomax | Marketing and promotion agreement under which Oryx will market Angiomax in Canada (10/31) |
Unigene | Upsher-Smith Laboratories Inc. | A nasal version | The marketing agreement includes an up- front payment to Unigene of $3M; Unigene will manufacture the product for packaging and distribution nationwide by Upsher-Smith (12/2) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
** Denotes the date the item ran in BioWorld International. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange | |||
To read more on related topics, click on one of the words below.